BIO 2016

Califf: New FDA guidance to ensure all drug info is available to patients

By Dan Stanton contact

- Last updated on GMT

Related tags: Social media, Food and drug administration, Fda

FDA Commissioner Robert Califf was speaking at BIO. Image: Wikimedia/Michael J. Ermarth
FDA Commissioner Robert Califf was speaking at BIO. Image: Wikimedia/Michael J. Ermarth
Expect industry guidance on product communication soon says US FDA Commissioner Robert Califf, though a more pragmatic approach to social media will be taken.

Industry’s responsibility to communicate on and off-label information to patients will be targeted in upcoming guidance, Califf said during a fireside chat at BIO in San Francisco last week.

“This is a matter of great personal interest to me. People do not know how to use products in the ideal way,”​ he told the packed room.

“I’ve had a lot of experience working with industry in my past, I have great respect for industry, but in general as a professional I’ve not looked to industry to be the least biased source of information. So to the extent that industry has information, it’s definitely my goal to get it out there, I just want to make every effort to have it to go through channels which don’t have bias.”

Presently some information held by a company is not public but communicated privately to physicians and clinicians, he continued, calling for all information known about a drug or a medical advice to be made available either in the US Food and Drug Administration (FDA) label or via prescriber and patient information.

“If you have useful information from a human study, you have a commitment to make that knowledge public.”

Califf said the FDA would be issuing some guidelines “in the very near future”​ but was reticent to give more details.

Social Media

Califf also spoke on the FDA’s role in regulating the growing use of social media in the industry, describing how this could be a game-changer for both the Agency and drug companies.

“In the past we would depend on patient advocates; we might have talked to half a dozen people who might represent a million people with a disease. But now with social media and with the broad use of the internet we can communicate directly with people.”

However, he acknowledged there may also be concerns surrounding surreptitious advertising of both commercial products and those in development.

“Whether some of these details will need to be changed, I think we’ll learn as we go along. If we slip back just a couple of years it would be unimaginable that we would have billions of people with personal devices that could communicate so no one anticipated in the rules exactly what that regulatory scheme should look like.”

His comments come two years after the Agency’s first attempt at drawing up guidance​ was lambasted by a number of Big Pharma firms.

Related topics: Markets & Regulations, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars